Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

PURPOSE: Nivolumab, a human immunoglobulin G(4)–blocking antibody against the T-cell programmed death-1 checkpoint protein, has activity against metastatic melanoma. Its safety, clinical efficacy, and correlative biomarkers were assessed with or without a peptide vaccine in ipilimumab-refractory and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Weber, Jeffrey S., Kudchadkar, Ragini Reiney, Yu, Bin, Gallenstein, Donna, Horak, Christine E., Inzunza, H. David, Zhao, Xiuhua, Martinez, Alberto J., Wang, Wenshi, Gibney, Geoffrey, Kroeger, Jodi, Eysmans, Cabell, Sarnaik, Amod A., Chen, Y. Ann
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3837092/
https://ncbi.nlm.nih.gov/pubmed/24145345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.51.4802
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados